Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
43 hedge funds and large institutions have $52.4M invested in Kindred Biosciences, Inc. in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 41 → 43 (+2)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
2.68% less ownership
Funds ownership: 64.58% → 61.9% (-2.7%)
18% less capital invested
Capital invested by funds: $64.1M → $52.4M (-$11.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.6M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.34M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$740K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$565K |
| 5 |
AI
Ariel Investments
Chicago,
Illinois
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$15M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.17M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$529K |
| 4 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$232K |
| 5 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$227K |
KIN Hedge Fund Activity: Q4 2016 in Review
43 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2016, worth a combined $52.4M — down 18% from $64.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KIN positions and 5 closed out — a net gain of 2 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.6M. The largest seller was Baupost Group, exiting entirely with an estimated $15M sold.
- 43 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2016, up from 41 in Q3 2016.
- Funds reported $52.4M of Kindred Biosciences, Inc. stock for Q4 2016, down 18% quarter-over-quarter.
- 7 funds opened new Kindred Biosciences, Inc. positions in Q4 2016 and 5 closed out, a net change of +2 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2016 was Morgan Stanley, an estimated $8.6M added.
- The largest Kindred Biosciences, Inc. seller in Q4 2016 was Baupost Group, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2016.